Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL） (PRECAL)

20. července 2026 aktualizováno: Tang-Du Hospital

Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy: A Prospective, Multicenter, Observational Clinical Study

This is a national prospective, multicenter, observational study. A total of 200 eligible patients will be enrolled from 10 hospitals across the country. Inclusion criteria are as follows: aged ≥ 18 years; diagnosed with moderate-to-severe active ulcerative colitis (UC); disease extent classified as E2 or E3; receiving biologic therapy for the first time; and having a confirmed UC diagnosis for more than 3 months. The follow-up period lasts 30-32 weeks. Six scheduled follow-up visits will be conducted at baseline, weeks 2-4, 6-8, 14-16, 22-24, and 30-32 after enrollment. The study endpoints are defined as: endoscopic mucosal healing (Mayo endoscopic score = 0 for UC), clinical judgment of inadequate response to current biologic therapy (i.e., continued treatment is unlikely to achieve mucosal healing and thus treatment switching or combined medication is required), or completion of the 30-32-week follow-up. The primary objective is to determine the cutoff value and predictive efficacy of the early (Weeks 2-4) reduction in fecal calprotectin (FC) measured by magnetic particle chemiluminescence assay for predicting mucosal healing in moderate-to-severe UC patients initiating biologic therapy.

Přehled studie

Postavení

Zápis na pozvánku

Podmínky

Intervence / Léčba

Detailní popis

Ulcerative colitis (UC) is a chronic non-specific inflammatory bowel disease that mainly affects the rectum and colon. It is characterized by frequent relapse and protracted course. Its incidence has been rising rapidly, imposing a substantial economic burden on both patients and society. Biologic agents serve as key therapeutic options for UC and are widely used in the management of patients with moderate-to-severe disease. Mucosal healing (MH) is a core therapeutic goal for UC. Endoscopy is the primary modality to assess endoscopic MH, yet it is an invasive examination.

Fecal calprotectin (FC) is a specific biomarker for intestinal inflammation, which can accurately reflect the inflammatory status of the gut and acts as an ideal non-invasive biomarker for patients with UC. A large number of existing studies have demonstrated that FC is strongly correlated with clinical disease activity, endoscopic findings and histological parameters, highlighting its great value in disease assessment.

Magnetic particle chemiluminescence assay features high sensitivity, rapid detection, wide linear range, excellent precision and accuracy, as well as high degree of automation. It enables full-course monitoring of FC levels across mild, moderate and severe inflammatory stages as well as disease remission, providing evidence for evaluating therapeutic efficacy and optimizing treatment regimens. Hence, it is an optimal method for detecting FC concentrations.

This is a national prospective, multicenter, observational study. Eligible participants are patients aged 18 years or older with moderate-to-severe active UC, disease extent classified as Montreal E2 or E3, newly initiated biologic therapy, and a confirmed UC diagnosis of more than 3 months. The total follow-up duration is 30 to 32 weeks. During follow-up, stool samples are collected for FC measurement, along with clinical data and endoscopic results of the enrolled patients.

The study endpoints are defined as endoscopic mucosal healing, clinically confirmed inadequate response to the current biologic therapy (where continued treatment is unlikely to achieve mucosal healing, necessitating treatment switching or combined medication), or completion of the 30-32-week follow-up.

The primary objective is to determine the cutoff value and predictive performance of the early (Weeks 2-4) reduction in FC measured by magnetic particle chemiluminescence assay for predicting mucosal healing in moderate-to-severe UC patients receiving initial biologic therapy.

The secondary objectives are as follows:

  1. To identify the cutoff value and predictive performance of the early (Weeks 2-4) FC reduction detected via magnetic particle chemiluminescence assay for predicting sustained clinical response in moderate-to-severe UC patients on initial biologic therapy;
  2. To explore the cutoff value and predictive performance of the early (Weeks 2-4) FC reduction for predicting sustained endoscopic remission in the above patient population;
  3. To analyze the dynamic correlation between FC levels measured by magnetic particle chemiluminescence assay and clinical disease activity;
  4. To assess the correlation between FC levels and endoscopic disease activity;
  5. To establish a predictive model for mucosal healing at Weeks 30-32 in UC patients by combining symptom scores, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), FC levels and their reduction ranges.

Typ studie

Pozorovací

Zápis (Odhadovaný)

200

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Čína
      • Dalian, Čína, 116023
        • The Second Hospital of Dalian Medical University
    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100044
        • Peking University People's Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Čína, 401121
        • Chongqing General Hospital
    • Guangdong
      • Shenzhen, Guangdong, Čína, 518101
        • Shenzhen Hospital, Southern Medical University
    • Hubei
      • Wuhan, Hubei, Čína, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210009
        • Zhongda Hospital, Southeast University
    • Liaoning
      • Shengyang, Liaoning, Čína, 110004
        • Shengjing Hospital of China Medical University,
    • Shandong
      • Qingdao, Shandong, Čína, 266035
        • Qilu Hospital (Qingdao), Shandong University
    • Shanxi
      • Xi’an, Shanxi, Čína, 710038
        • Tangdu Hospital, Air Force Medical University
      • Xi’an, Shanxi, Čína, 710077
        • The First Affiliated Hospital of Xi'an Medical University

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Patients with ulcerative colitis who are aged ≥ 18 years, have moderate-to-severe disease activity, present with disease extent E2 or E3, receive biologic therapy for the first time, and have a confirmed diagnosis of ulcerative colitis for more than 3 months

Popis

Inclusion Criteria

  • Aged ≥ 18 years;
  • Patients with ulcerative colitis receiving initial biologic therapy;
  • Confirmed diagnosis of ulcerative colitis for more than 3 months;
  • Moderate-to-severe disease activity;
  • Disease extent classified as E2 or E3;
  • Voluntarily signed the informed consent form and agreed to participate in this study.

Exclusion Criteria

  • Aged under 18 years;
  • Patients who have previously received biologic therapy;
  • Patients with ulcerative colitis of disease extent E1;
  • Pregnant or lactating women;
  • Patients with contraindications to biologic agents;
  • Patients deemed unsuitable for this clinical study by clinical judgment.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
moderate-to-severe UC patients
Patients with ulcerative colitis who are aged ≥ 18 years, have moderate-to-severe disease activity, present with disease extent E2 or E3, receive biologic therapy for the first time, and have a confirmed diagnosis of ulcerative colitis for more than 3 months
Diagnostický test: fecal calprotectin test
Fecal calprotectin detection by magnetic particle chemiluminescence assay

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cut-off value and predictive efficacy of the early decline in fecal calprotectin for mucosal healing
Časové okno: From enrollment to at the end of 30-32 weeks
Mucosal healing was defined as an endoscopic subscore of 0 according to the modified Mayo score system for assessing ulcerative colitis disease activity
From enrollment to at the end of 30-32 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cutoff value and predictive performance of fecal calprotectin reduction for predicting sustained clinical response
Časové okno: From enrollment to at the end of 30-32 weeks follow-up
clinical symptom remission is defined as a score of 0 for both Stool Frequency (SF) and Rectal Bleeding(RB) in the Mayo score; or a score of 0 for RB, plus an SF score of ≤1 with a reduction of at least 1 point from baseline
From enrollment to at the end of 30-32 weeks follow-up
Cutoff value and predictive performance of fecal calprotectin reduction for predicting sustained endoscopic remission
Časové okno: From enrollment to at the end of 30-32 weeks follow-up
Endoscopic remission is defined as an endoscopic subscore of 0 or 1 in the Mayo score (excluding the finding of mucosal friability)
From enrollment to at the end of 30-32 weeks follow-up
Dynamic correlation between fecal calprotectin levels and clinical disease activity
Časové okno: From enrollment to at the end of 30-32 weeks follow-up
Fecal calprotectin and Mayo score data will be collected at each follow-up time point to analyze their dynamic correlation
From enrollment to at the end of 30-32 weeks follow-up
Correlation between fecal calprotectin levels and endoscopic disease activity.
Časové okno: From enrollment to at the end of 30-32 weeks follow-up
Fecal calprotectin and Mayo endoscopic subscore data will be collected at each follow-up time point to assess their correlation.
From enrollment to at the end of 30-32 weeks follow-up

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Predictive model for mucosal healing at Weeks 30-32 in UC patients by combining symptom scores, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin levels and their decreasing ranges
Časové okno: From enrollment to at the end of 30-32 weeks follow-up
Multivariate regression analysis will be performed using patients' demographic data, disease characteristics, medication information, Mayo scores, ESR, CRP and fecal calprotectin levels, so as to develop a predictive model for mucosal healing at Weeks 30-32 among moderate-to-severe ulcerative colitis patients treated with biologic agents.
From enrollment to at the end of 30-32 weeks follow-up

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Tang-Du Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

18. června 2026

Primární dokončení (Odhadovaný)

30. června 2027

Dokončení studie (Odhadovaný)

30. října 2027

Termíny zápisu do studia

První předloženo

28. června 2026

První předloženo, které splnilo kritéria kontroly kvality

20. července 2026

První zveřejněno (Aktuální)

23. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

23. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

20. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • FCTSTUDY001

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Ulcerózní kolitida (UC)

Klinické studie na fecal calprotectin test

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Slovakia

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit